HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC
Journal
Future oncology (London, England)
Journal Volume
19
Journal Issue
19
Date Issued
2023-06
Author(s)
Yu, Helena A
Hayashi, Hidetoshi
Goto, Yasushi
Felip, Enriqueta
Reck, Martin
Vigliotti, Michele
Dong, Qian
Cantero, Frédérique
Fan, Pang-Dian
Kanai, Masayuki
Sternberg, David W
Jänne, Pasi A
Abstract
Limited treatment options exist for EGFR-mutated NSCLC that has progressed after EGFR TKI and platinum-based chemotherapy. HER3 is highly expressed in EGFR-mutated NSCLC, and its expression is associated with poor prognosis in some patients. Patritumab deruxtecan (HER3-DXd) is an investigational, potential first-in-class, HER3-directed antibody-drug conjugate consisting of a HER3 antibody attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. In an ongoing phase I study, HER3-DXd demonstrated promising antitumor activity and a tolerable safety profile in patients with EGFR-mutated NSCLC, with or without identified EGFR TKI resistance mechanisms, providing proof of concept of HER3-DXd. HERTHENA-Lung01 is a global, registrational, phase II trial further evaluating HER3-DXd in previously treated advanced EGFR-mutated NSCLC. Clinical Trial Registration: NCT04619004 (ClinicalTrials.gov); 2020-000730-17 (EudraCT).
Subjects
EGFR mutation; HER3-DXd; antibody–drug conjugate; non-small-cell lung cancer; patritumab deruxtecan
SDGs
Type
review